China’s Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285) announced plans to acquire a 90% ownership stake in Yingu Pharmaceutical Co., Ltd. for a consideration of RMB 704 million (USD 97 million). The deal underscores Lingrui’s strategic expansion in the pharmaceutical sector, targeting Yingu’s innovative product portfolio.
Yingu Pharma’s Innovative Nasal Spray
Yingu Pharmaceutical is known for its bencycloquidium bromide nasal spray, which is hailed as the first home-grown anticholinergic receptor antagonist in China. This nasal spray is the only approved anticholinergic drug for the treatment of allergic rhinitis in the country, positioning Yingu as a leader in this therapeutic area.
Strategic Implications for Lingrui
The acquisition of Yingu Pharma will significantly enhance Henan Lingrui’s product offerings, particularly in the area of respiratory treatments. By integrating Yingu’s innovative nasal spray into its portfolio, Lingrui aims to strengthen its market position and expand its reach in the domestic pharmaceutical market.-Fineline Info & Tech
